Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.

Annals of hematology - 1 Jan 2019

Gao Xiao-Ning, Lin Ji, Wang Shu-Hong, Huang Wen-Rong, Li Fei, Li Hong-Hua, Chen Jing, Wang Li-Jun, Gao Chun-Ji, Yu Li, Liu Dai-Hong

Abstract excerpt

Unmanipulated haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma. Relapse is the main cause of treatment failure for patients with relapsed/refractory disease or with very high-risk gene mutations such as TP53, TET2, and DNMT3a. In this study, we aimed to establish the tolerance and efficacy of prophylactic donor lymphocyte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allografts
Share to Blood Donors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Graft vs Host Disease

Share to Leukemia

Share to Lymphoma

Share to Recurrence

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 30143831
DOI: 10.1007/s00277-018-3482-7
PMCID: PMC6334751

Genes

TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.PMID 30143831Read ↗

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study.Semantic proximity Read ↗

Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donorsSemantic proximity Read ↗

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationSemantic proximity Read ↗

Relapse after Allogeneic Hematopoietic Cell TherapySemantic proximity Read ↗

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after TransplantationSemantic proximity Read ↗

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk B-cell Lymphoma Patients: Final Long-term Analysis From a Prospective Multicenter Phase-ii TrialSemantic proximity Read ↗

Peripheral Blood Hematopoietic Stem Cells for Transplantation of Hematological Diseases from Related, Haploidentical Donors after Reduced-Intensity ConditioningSemantic proximity Read ↗

Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in JapanSemantic proximity Read ↗

Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.Semantic proximity Read ↗

Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant.Semantic proximity Read ↗

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.